









Markets
/
Stocks
/
nasdaq-traw
/

Traws Pharma Inc

TRAW

1.760USD

-0.170-8.81%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

81.55Market Cap

0.02P/E TTM



Traws Pharma Inc

1.760

-0.170-8.81%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Traws Pharma Inc

Currency: USD Updated: 2026-03-27

Key Insights

Traws Pharma Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 121 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.25.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Traws Pharma Inc's Score

Industry at a Glance

Industry Ranking

121 / 391

Overall Ranking

240 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Traws Pharma Inc Highlights

StrengthsRisks

Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.

Growing

The company is in a growing phase, with the latest annual income totaling USD 226.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 226.00K.

Overvalued

The company’s latest PE is 0.02, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.90M shares, increasing 3.99% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 87.26K shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

7.250

Target Price

+275.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Traws Pharma Inc is 8.03, ranking 54 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 64.19%.

Score

Industry at a Glance

Previous score

9.52

Change

-1.49



Financials

9.74

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.86

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.58

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Traws Pharma Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Traws Pharma Inc is 7.19, ranking 152 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.02, which is 64.64% below the recent high of 0.03 and 8749.72% above the recent low of -1.57.

Score

Industry at a Glance

Previous score

7.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 121/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Traws Pharma Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 8.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

7.250

Target Price

+311.93%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Traws Pharma Inc

TRAW

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Traws Pharma Inc is 5.87, ranking 295 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.30 and the support level at 1.36, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.14

Change

-0.27

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.056

Neutral

RSI(14)

43.063

Neutral

STOCH(KDJ)(9,3,3)

13.858

Sell

ATR(14)

0.252

Low Volatility

CCI(14)

-149.143

Sell

Williams %R

93.333

Oversold

TRIX(12,20)

0.630

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.918

Sell

MA10

2.035

Sell

MA20

1.920

Sell

MA50

1.969

Sell

MA100

1.920

Sell

MA200

1.892

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Traws Pharma Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 23.82%, representing a quarter-over-quarter decrease of 3.46%. The largest institutional shareholder is The Vanguard, holding a total of 87.26K shares, representing 1.09% of shares outstanding, with 320.81% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Adage Capital Management, L.P.

330.00K

Squadron Capital Management LLC

591.00K

Ikarian Capital LLC

28.49K

Viriom Inc

605.53K

OrbiMed Advisors, LLC

605.53K

Savchuk (Nikolay)

268.32K

+6.52%

Dukes (Iain D)

118.14K

+45.50%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Traws Pharma Inc is 1.34, ranking 318 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.